Kinases (Tyrosine Specific Protein)
Tyrosine specific kinases form a large family of enzymes that are responsible for catalyzing the transfer of ATP to specific tyrosine residues in target proteins. In turn, the phosphorylation of tyrosine residues causes a change in the function of the protein that they are contained in. They function in a variety of processes, signal transduction pathways, and actions, and may be responsible for key events in the body[1]. Axon Ligands™ that interact with tyrosine specific enzymes that are part of the JAK/STAT signaling pathway have been categorized independently. The remainder of Axon Ligands™ that lack interactions with tyrosine kinases of this particular signaling pathway are listed here, grouped on the basis of their selectivity.
[1] Receptor tyrosine kinase signaling: a view from quantitative proteomics. J. Dengjel,I. Kratchmarova, B. Blagoev. Mol. Biosyst. 2009, 5, 1112-1121.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 1378 | AG 490 | JAK2 inhibitor | €65.00 | |
| 1778 | AZ 960 | JAK2 inhibitor | €95.00 | |
| 3855 | AZD-4205 | Selective and ATP-competitive inhibitor of JAK1 | Inquire | |
| 1955 | Baricitinib | Inhibitor of JAK1 and JAK2 | €70.00 | |
| 3813 | BMS-911543 | Potent, selective and orally active inhibitor of JAK2 | Inquire | |
| 3671 | CEP-33779 | Potent, selective and orally bioavailable JAK2 inhibitor | €95.00 | |
| 1338 | CP 690550 | JAK3 inhibitor | €60.00 | |
| 3861 | Decernotinib | Potent and selective,orally bioavailable Janus kinase 3 (JAK3) inhibitor | Inquire | |
| 4091 | Deucravacitinib | Potent, highly selective, allosteric and orally bioavailable TYK2 inhibitor | €150.00 | |
| 4006 | GLPG-0634 | The first orally-available, selective inhibitor of JAK1 | Inquire | |
| 1843 | JAK2 inhibitor 13 | JAK2 inhibitor | €110.00 | |
| 2554 | LY 2784544 | Potent, selective and ATP-competitive inhibitor of mutated janus kinase 2 (JAK2V617F) | €95.00 | |
| 1681 | Momelotinib | JAK1 and JAK2 inhibitor | €80.00 | |
| 4124 | Momelotinib hydrochloride | JAK1 and JAK2 inhibitor | €120.00 | |
| 2792 | NVP-BSK805 | Potent, selective and orally bioavailable JAK2 inhibitor | €125.00 | |
| 3950 | Peficitinib | Potent and orally bioavailable JAK inhibitor | €120.00 | |
| 2217 | PF 956980 | JAK3 inhibitor; analogue of Axon 1338 and 2072 | €90.00 | |
| 1598 | Ruxolitinib | JAK1 and JAK2 inhibitor | €65.00 | |
| 2539 | Solcitinib | Selective JAK1 inhibitor for treatment of degenerative and inflammatory diseases | €90.00 | |
| 1588 | TG 101348 | JAK2 inhibitor | €80.00 | |
| 2072 | Tofacitinib citrate | Potent Janus Kinase 3 (JAK3) inhibitor | €115.00 | |
| 2316 | WP 1066 | Potent JAK2 and STAT3 inhibitor and downregulator of antiapoptotic proteins | €95.00 | |
| 2231 | XL 019 | JAK2 inhibitor | €100.00 | |